ARS Tangible Asset Value from 2010 to 2026
| SPRY Stock | 9.67 0.47 4.64% |
Tangible Asset Value | First Reported 2010-12-31 | Previous Quarter 0.0 | Current Value 0.0 | Quarterly Volatility 0.0 |
Check ARS Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ARS Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 67.5 K, Gross Profit of 82.8 M or Other Operating Expenses of 111.4 M, as well as many indicators such as Price To Sales Ratio of 9.81, Dividend Yield of 0.0 or PTB Ratio of 3.76. ARS financial statements analysis is a perfect complement when working with ARS Pharmaceuticals Valuation or Volatility modules.
ARS | Tangible Asset Value | Build AI portfolio with ARS Stock |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for ARS Stock Analysis
When running ARS Pharmaceuticals' price analysis, check to measure ARS Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ARS Pharmaceuticals is operating at the current time. Most of ARS Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ARS Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ARS Pharmaceuticals' price. Additionally, you may evaluate how the addition of ARS Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.